Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Urologic Neoplasms: early-phase trial registry
2 of 9 indexed Urologic Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 2 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Urologic Neoplasms: 9 US clinical trials tracked, 2 recruiting.
Urologic Neoplasms is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Lipac Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition urologic-neoplasms
OPEN 2 | RECR 22% | LATE 1 | EARLY 6 | RANK #1916 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acne (22% recruiting · 27 trials)
Urologic Neoplasms lists 2 open slots (22% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Urologic Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Urologic Neoplasms is recruiting below its size-band peers.
2 of 9 indexed trials (22.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Urologic Neoplasms trials is spread across many organizations.
Lipac Oncology accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Urologic Neoplasms enrolment sits around 60 participants.
Median target enrolment is 60 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.
-
Urologic Neoplasms research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Cedars-Sinai Medical Center
NCT04442724
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
Dana-Farber Cancer Institute
NCT05899361
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Astellas Pharma Global Development
NCT03288545
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen, a wholly owned subsidiary of Pfizer
NCT04579380
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
NCT03091192
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Astellas Pharma
NCT03219333
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Achieve Life Sciences
NCT01454089
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
Pharmacyclics
NCT00134186
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology
NCT03081858
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Urologic Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Urologic Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Urologic Neoplasms page
9 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Urologic Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Lipac Oncology sponsors the most Urologic Neoplasms trials on record, review their full trial history before evaluating a specific study. See Lipac Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urologic Neoplasms condition card totals 9 registered trials; most-linked intervention TSD-001; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.